AM833

AM833 (Cagrilintide) is a long-acting amylin analogue supplied as a research peptide for laboratory investigation only. It is studied within the amylin and calcitonin receptor signalling class and is not an approved therapeutic good in Australia. This listing is intended solely for qualified researchers requiring a well-characterised reference peptide for in-vitro and preclinical study.

Research Background

Amylin analogues are examined in laboratory research on the amylin receptor system, a complex formed by the calcitonin receptor together with receptor-activity-modifying proteins (RAMPs). Cagrilintide has been investigated as a structurally stabilised analogue used to study amylinergic signalling and its interaction with central satiety and metabolic pathways in preclinical models. Its extended profile has made it a useful tool for examining receptor engagement and analogue stability under controlled laboratory conditions.

Research interest in AM833 frequently centres on its role as a comparator or co-reference alongside incretin-based compounds, where investigators explore combined amylin and GLP-1 receptor signalling in laboratory systems. Studies typically assess receptor-binding profiles across the amylin receptor subtypes, cyclic AMP signal-transduction assays, and the structural determinants of analogue half-life and stability, contributing to the broader understanding of amylinergic pharmacology without reference to human administration. Comparative studies frequently pair amylin analogues with incretin-class reference compounds to examine how distinct receptor systems contribute to metabolic signalling, and AM833 provides a well-defined anchor for such panels. This positions it as a practical reagent for assay validation, method development, and reproducibility checks within metabolic research programmes.

AM833 (Cagrilintide) Specifications & Handling

• Purity: ≥99% as determined by analytical testing
• Verification: independent third-party HPLC and mass spectrometry, with a batch-specific Certificate of Analysis (COA) available for laboratory records
• Physical form: lyophilised white powder
• Storage: store the lyophilised peptide at -20°C, kept desiccated and protected from light for long-term stability
• Reconstitution: reconstitute in bacteriostatic or sterile water for laboratory handling; keep the reconstituted solution refrigerated at 2-8°C and use it within the working window generally recommended for peptide stability
• Handling: intended for use by qualified laboratory personnel using appropriate personal protective equipment in a suitable controlled environment
• Documentation: batch COA supplied on request to support internal verification and traceability records

Related Research Compounds

Researchers studying amylin and incretin signalling may also wish to reference Mazdutide, Survodutide, and LY3437943, each of which is examined within overlapping metabolic-signalling frameworks. Explore the full catalogue of GLP-1 peptides for additional reference materials and comparison compounds.

All peptides listed are supplied strictly for in-vitro and laboratory research use only. They are not intended for human or veterinary use, diagnosis, treatment, or any weight-management application. Researchers are responsible for ensuring full compliance with applicable Australian law and Therapeutic Goods Administration (TGA) regulations governing research chemicals.

For laboratory and research use only. This product is not for human or veterinary consumption, and nothing on this page is medical advice. Researchers are responsible for compliance with all applicable Australian laws (including TGA regulations) and institutional guidelines.